Condition: Respiratory Synctial Virus Infections · Sponsor: Meyer Children's Hospital IRCCS
This study aims to evaluate the impact of Nirsevimab, a monoclonal antibody used for RSV prophylaxis, on reducing RSV- related hospitalizations. It will be conducted at 8 pediatric departments in Tuscany, Italy. First, a matched case-control study investigates the real-world effectiveness of Nirsevimab in preventing RSV-related lower respiratory tract infection (LRTI) hospitalizations during the RSV epidemic season 2024-2025. Second, a descriptive study examines how the Nirsevimab immunization campaign affects RSV epidemiology, focusing on patients' age, comorbidities, infection severity, and clinical outcomes. The findings aim to optimize RSV prevention strategies and inform public health policies.
This description comes directly from the study's public registry record.
Giuseppe Indolfi · +3905556621 · giuseppe.indolfi@meyer.it
Always discuss trial participation with your own doctor first.
| SOC Pediatria Ospedale San Donato | Arezzo, Arezzo, Italy | Recruiting |
| SOC Pediatria Ospedale Santa Maria Annunziata | Bagno a Ripoli, Firenze, Italy | Recruiting |
| SOC Neonatologia e Terapia Intensiva Neonatale, Ospedale San Giovanni Di Dio | Florence, Firenze, Italy | Recruiting |
| Meyer Children's Hospital IRCCS | Florence, Italy, Italy | Recruiting |
| Azienda Ospedaliero Universitaria Pisana | Pisa, Italy, Italy | Recruiting |
| SOC Pediatria e Neonatologia Ospedale San Jacopo | Pistoia, Pistoia, Italy | Recruiting |
| SOC Pediatria e Neonatologia Ospedale Santo Stefano | Prato, Prato, Italy | Recruiting |
| SOC Pediatria AOU Senese | Siena, Siena, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06856967